Table 4.
Clinical profile of patients receiving edaravone treatment.
| Patient | Clinical diagnosis | Age/sex | Initiation and dosage of edaravone treatment | Other treatments | Outcomes |
|---|---|---|---|---|---|
| 1 | HHV-6 encephalopathy | 14 m/M | Day 5 0.5 mg/kg × 2/day × 7 days |
Mannitol, Dexamethasone, Ganciclovir, MDL, PHT |
Intellectual disability |
|
| |||||
| 2 | HHV-6 encephalopathy (AESD) |
12 m/F | Day 5 0.5 mg/kg × 2/day × 8 days |
Mannitol, Dexamethasone, Ganciclovir, DZP, MDL |
Without sequelae |
|
| |||||
| 3 | HHV-6 encephalopathy | 14 m/M | Day 4 0.5 mg/kg × 2/day × 10 days |
Mannitol, Dexamethasone, Ganciclovir/acyclovir, DZP, MDL |
Hemophagocytic syndrome Died of fulminant hepatitis |
|
| |||||
| 4 | HHV-6 encephalopathy (AESD) |
20 m/F | Day 7 0.5 mg/kg × 2/day × 7 days |
Mannitol, Dexamethasone, Aciclovir, MDL |
Lt hemiparesis |
|
| |||||
| 5 | HHV-6 encephalopathy (AESD) |
12 m/M | Day 3 15 mg/day × 10 days |
DZP, MDL, steroid pulse therapy, mild therapeutic hypothermia |
Moderate psychomotor retardation |
|
| |||||
| 6 | HHV-6 febrile seizures | 10 m/F | Day 1 0.5 mg/kg × 2/day × 12 days |
Mannitol, Dexamethasone, Ganciclovir/acyclovir, DZP, MDL, PHT |
Without sequelae |
m: months; M: male; F: female; DZP: diazepam; MDL: midazolam; PHT: phenytoin; Lt: left; HHV: human herpesvirus; AESD: acute encephalopathy with biphasic seizures and late reduced diffusion.